Bücher von Jagdish Kakadiya

Pharmacological evalution of anti-urolithiatic activity of an ayurvedic formulation Goumutradi Kshar in ethylene glycol induced urolithiasis in rats. 0.75% Ethylene glycol(EG) in drinking water for 28 days was used to induced urolithiasis in albino wister rats. Five groups (Normal Control, Disease Control, Preventive-225mg/kg, Treatment-225mg/kg, Treatment-150mg/kg) were taken & Six animals were taken in each group. An ayurvedic formulation Goumutradi Kshar was given 225mg/kg orally as prophylactic treatment & 225mg/kg & 150mg/kg orally as curative treatment. After completion of 28 days drug & EG treatment, 24hr urine, blood, kidney homogenate and kidney histopathology collections were done. It has been concluded that an ayurvedic formulation Goumutradi Kshar shows anti-urolithiatic acitivity in ethylene glycol induced urolithiasis in rats. It act as stone removal, as it inhibits crystal growth as well as it also decreased stone promoters level and increased stone inhibitor level. It has been also considered as potent diuretic since it increased urine volume in rats.

Diabetes Mellitus (DM) is a persistent metabolic cluster of diseases that involves erroneously excessive blood glucose levels and relative comorbidities. Dyslipidemia is one of the primarily occurred complications in Diabetic (DM) patients. This experimental study is aimed at investigating the effect of combination therapy of Empagliflozin + Colesevelam in Diabetic Dyslipidemia rats. Total number of 30 Albino Wistar rats were used for this study and HbA1C, Fasting Blood Glucose (FBG) like diabetic and HDL-c, LDL-c, TGs, Total Cholesterol (TC) like lipid parameters were estimated. Renal profile was evaluated by investigating animals for serum creatinine and Urinary albumin. Animals of the EMPA + BAS shows the decrease in Diabetic, Lipid and renal parameters than other groups. This study showed that Dyslipidemia is highly prevalent among TIIDM induced animals and combination of EMPA + BAS can be proven better therapy for Diabetic Dyslipidemia.

Atherosclerosis is a major cardio effective disorder that affects heart causing hyperlipidemia which blocks the artery, aorta and obstruct the pathway of blood flow which puts life at risk. The modern medication needs to be administered continuously and in higher doses which leads to negative drawbacks. The study aim is to give the Combination therapy treatment as per the drug mechanism of action is known and how bioavailability is also known. Five group of albino wistar rats were being experimented in this case, group I to V i.e. NC, DC, COL, ATS(40mg/kg) and ATS(10mg/kg) + COL is to give the treatment as chronopharmacology method in combination and in low dose range of atorvastatin 10-20 mg/kg less side effect is observed. Conducting the study is seen that lower dose in combination (bile acid sequestrants and HMG- CO-A inhibitor) was proven that CK-MB levels are decreased in comparison of high dose of Atrorvastatin by Detection of Biochemical Evaluation Parameters like CK-MB, Lipid profile, CBC etc. As further it will comes in future work can be done into cell line on molecular base to determine clinical significance.

O objectivo do presente estudo era avaliar o efeito cardio-protector do co-transportador-2 de glicose de sódio sozinho e a sua combinação com metformina em infarto do miocárdio induzido experimentalmente em ratos diabéticos. O grupo I serviu como controlo normal e recebeu veículo (0,5% de hidroxi-etilcelulose) durante 4 semanas e subcutânea salina normal no 29º e 30º dia. O Grupo II serviu como controlo diabético-micárdico e recebeu STZ-NIC (65-120mg/kg, i.p) e Isoproterenol (85mg/kg, sc) no 29º e 30º dia. O Grupo III recebeu STZ-NIC, ISO e Empagliflozin 5mg/kg. O Grupo IV recebeu STZ-NIC, ISO e Empagliflozin 10mg/kg. O Grupo V recebeu STZ-NIC, ISO e Empagliflozina 5mg/kg + Metformina 50mg/kg. Os animais tratados com a combinação de Empagliflozina e Metformina mostraram uma inibição significativa no nível elevado de BG, CK-MB, LDH, AST, Troponina e perfil lipídico em animais diabéticos em comparação com animais de controlo diabético (Grupo II) e animais dos Grupos III e IV que receberam apenas Empagliflozina 5 mg/kg e 10 mg/kg respectivamente.

L'obiettivo del presente studio è stato quello di valutare l'effetto cardioprotettivo dell'inibitore del co-trasportatore sodio-glucosio-2 da solo e della sua combinazione con la metformina nell'infarto miocardico indotto sperimentalmente nei ratti diabetici. Il gruppo I è servito come controllo normale e ha ricevuto il veicolo (idrossietilcellulosa allo 0,5%) per 4 settimane e la normale soluzione fisiologica per via sottocutanea il 29° e 30° giorno. Il gruppo II è servito come controllo diabetico-miocardico e ha ricevuto STZ-NIC (65-120mg/kg, i.p) e isoproterenolo (85mg/kg, sc) il 29 e 30 giorni. Il gruppo III ha ricevuto STZ-NIC, ISO ed Empagliflozin 5mg/kg. Il gruppo IV ha ricevuto STZ-NIC, ISO ed Empagliflozin 10mg/kg. Il gruppo V ha ricevuto STZ-NIC, ISO ed Empagliflozin 5mg/kg + Metformina 50mg/kg. Gli animali trattati con la combinazione di Empagliflozin e Metformina hanno mostrato una significativa inibizione dei livelli elevati di BG, CK-MB, LDH, AST, Troponina e del profilo lipidico negli animali diabetici rispetto agli animali di controllo diabetici (gruppo II) e agli animali dei gruppi III e IV che hanno ricevuto solo Empagliflozin 5 mg/kg e 10 mg/kg rispettivamente.

L'objectif de cette étude était d'évaluer l'effet cardio-protecteur de l'inhibiteur de sodium glucose co-transporteur-2 seul et de son association avec la metformine dans l'infarctus du myocarde induit expérimentalement chez les rats diabétiques. Le groupe I a servi de contrôle normal et a reçu un véhicule (hydroxyéthylcellulose à 0,5 %) pendant 4 semaines et une solution saline normale par voie sous-cutanée les 29e et 30e jours. Le groupe II a servi de contrôle diabétique-myocardique et a reçu du STZ-NIC (65-120mg/kg, i.p.) et de l'Isoprotérénol (85mg/kg, sc) les 29ème et 30ème jours. Le groupe III a reçu STZ-NIC, ISO et Empagliflozin 5mg/kg. Le groupe IV a reçu STZ-NIC, ISO et Empagliflozin 10mg/kg. Le groupe V a reçu STZ-NIC, ISO et Empagliflozin 5mg/kg + Metformin 50mg/kg. Les animaux traités avec l'association Empagliflozin et Metformin ont montré une inhibition significative du niveau élevé de BG, CK-MB, LDH, AST, Troponin et du profil lipidique chez les animaux diabétiques par rapport aux animaux diabétiques témoins (groupe II) et aux animaux des groupes III et IV recevant uniquement Empagliflozin 5 mg/kg et 10 mg/kg respectivement.

El objetivo del presente estudio fue evaluar el efecto cardioprotector del inhibidor del cotransportador de glucosa de sodio 2 solo y su combinación con metformina en el infarto de miocardio inducido experimentalmente en ratas diabéticas. El grupo I sirvió de control normal y recibió el vehículo (hidroxietilcelulosa al 0,5%) durante 4 semanas y solución salina normal por vía subcutánea los días 29 y 30. El grupo II sirvió de control diabético-miocárdico y recibió STZ-NIC (65-120mg/kg, i.p) e Isoproterenol (85mg/kg, sc) los días 29 y 30. El grupo III recibió STZ-NIC, ISO y Empagliflozin 5mg/kg. El grupo IV recibió STZ-NIC, ISO y Empagliflozin 10mg/kg. El grupo V recibió STZ-NIC, ISO y Empagliflozin 5mg/kg + Metformin 50mg/kg. Los animales tratados con la combinación de Empagliflozin y Metformin mostraron una inhibición significativa en el nivel elevado de BG, CK-MB, LDH, AST, Troponin y el perfil de lípidos en los animales diabéticos en comparación con los animales de control diabético (Grupo II) y los animales del Grupo III y IV que recibieron sólo Empagliflozin 5 mg/kg y 10 mg/kg respectivamente.

Ziel der vorliegenden Studie war es, die kardioprotektive Wirkung des Natrium-Glukose-Co-Transporter-2-Inhibitors allein und in Kombination mit Metformin bei einem experimentell induzierten Myokardinfarkt bei diabetischen Ratten zu untersuchen. Gruppe I diente als normale Kontrolle und erhielt 4 Wochen lang Vehikel (0,5% Hydroxyethylcellulose) und am 29. und 30. Tag subkutan normale Kochsalzlösung. Gruppe II diente als diabetisch-myokardiale Kontrolle und erhielt am 29. und 30. Tag STZ-NIC (65-120mg/kg, i.p) und Isoproterenol (85mg/kg, sc). Gruppe III erhielt STZ-NIC, ISO und Empagliflozin 5mg/kg. Gruppe IV erhielt STZ-NIC, ISO und Empagliflozin 10mg/kg. Gruppe V erhielt STZ-NIC, ISO und Empagliflozin 5mg/kg + Metformin 50mg/kg. Tiere, die mit der Kombination von Empagliflozin und Metformin behandelt wurden, zeigten eine signifikante Hemmung der erhöhten BZ-, CK-MB-, LDH-, AST- und Troponin-Werte sowie des Lipidprofils bei den diabetischen Tieren im Vergleich zu den diabetischen Kontrolltieren (Gruppe II) und den Tieren der Gruppen III und IV, die nur Empagliflozin 5 mg/kg bzw. 10 mg/kg erhielten.